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Abstract 
The detection of unknown mutations remains a serious challenge and, despite the expected 
benefits for the patient’s health, a large number of genes are not screened on a routine basis. 
We present the diagnostic application of EMMA (Enhanced Mismatch Mutation Analysis®, 
Fluigent), a novel method based on heteroduplex analysis by capillary electrophoresis using 
innovative matrices. BRCA1 and BRCA2 were screened for point mutations and large 
rearrangements in 1,525 unrelated patients (372 for the validation step and 1,153 in routine 
diagnosis) using a single analytical condition. Seven working days were needed for complete 
BRCA1/2 screening in 30 patients by one technician (excluding DNA extraction and 
sequencing). A total of 137 mutations were found, including a BRCA2 duplication of exons 19 
and 20, previously missed by Comprehensive BRACAnalysis®. The mutation detection rate 
was 11.9%, which is consistent with patient inclusions.  
This study therefore suggests that EMMA represents a valuable short-term and mid-
term option for many diagnostic laboratories looking for an easy, reliable and affordable 
strategy, enabling fast and sensitive analysis for a large number of genes. 
 
Key words: 
BRCA1, BRCA2, mutation, screening, diagnosis, capillary electrophoresis, EMMA
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INTRODUCTION 
 
The role of genetic screening is becoming increasingly important in cancer diagnosis, 
prognosis and treatment decisions. Developing fast, reliable and inexpensive methods to 
detect such mutations is therefore a major challenge for medicine. 
 Two main strategies are used to search for unknown mutations: direct sequencing and 
screening. The first strategy is currently considered to be the most reliable, although not 
totally flawless (Eng, et al., 2001). More specifically, reliable chemistry and software are 
prominent points to consider. 
The second strategy is a two-step strategy involving preliminary screening for the presence of 
variants on amplicons, followed by sequencing of only those fragment(s) in which a variation 
was detected. This dramatically reduces the number of fragments that need to be sequenced. 
These screening strategies are mainly based on heteroduplex analysis (HDA), using either a 
dedicated liquid chromatographic system (Denaturing High Performance Liquid 
Chromatography, DHPLC)(Spiegelman, et al., 2000) or a real-time PCR machine (High 
Resolution Melting curve analysis, HRM)(Wittwer, 2009). During a slow cool-down 
performed at the end of PCR amplification of a DNA fragm nt from a heterozygote sample, 
two homoduplex fragments (corresponding to the normal and mutated allele, respectively) 
and two heteroduplexes (with mismatched strands due to hybridization of a wild-type strand 
with a mutant strand) are obtained. The aim of HDA is to check for the presence of 
heteroduplexes. DHPLC and HRM are widely used in diagnostic laboratories. However, 
analysis conditions depend on melting domains, and optimization is required for each PCR 
fragment. 
HDA can also be performed by electrophoresis: homoduplexes are separated from 
heteroduplexes due to differences in electrophoretic mobility. Separations are nowadays 
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mostly performed by multi-capillary electrophoresis, allowing for high automation, low cost 
and high throughput, as recently described in a diagnostic validation of Conformation-
Sensitive Capillary Electrophoresis (Mattocks, et al.) . A novel HDA method has been 
recently developed (Houdayer, et al.2010). This method, called Enhanced Mismatch Mutation 
Analysis (EMMA) is based on the use of innovative matrices increasing the electrophoretic 
mobility differences between homoduplex and heteroduplex DNA (Weber, et al., 2004). 
Sensitivity is further improved by using nucleosides as additives to enhance single-base 
substitution detection. Nucleosides are expected to interact with mismatched bases of 
heteroduplexes, thereby increasing mobility differences with homoduplexes (Weber, et al., 
2006). Moreover, this method, in combination with adapted semiquantitative PCR conditions, 
can be used to simultaneously detect point mutations and large-scale rearrangement in a single 
run (Weber, et al., 2007). This feature, combined with the use of a single set of separation 
conditions for all fragments and with the multiplexing capability of the method, leads to a 
considerable simplification and cost reduction compared to previous methods. 
The use of EMMA for fast screening of BRCA1 and BRCA2 point mutations and large 
rearrangements is described below. Constitutional mutations of the BRCA1 [MIM 113705] 
and BRCA2 [MIM 600185] genes are associated with a risk of hereditary breast and ovarian 
cancer (HBOC). It is essential to identify BRCA1/2 mutations to provide appropriate 
counseling to patients and relatives, but this represents a challenging and time-consuming 
task, as the vast majority of mutations are unique and spread over the entire coding sequence. 
In this paper, we report the results of BRCA1 and BRCA2 screening for point mutations and 
large rearrangements in 1,525 unrelated patients (372 for the validation step and 1,153 in 
routine diagnosis), and discuss the performance of this new strategy. 
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PATIENTS AND METHODS 
 
Patients 
Genetic testing for BRCA1 and BRCA2 was proposed to women based on individual and/or 
family history (herein defined as index cases i.e. the first family member in whom complete 
BRCA1/2 gene screening was performed). Individual inclusion criteria included: i) breast 
adenocarcinoma before the age of 36, ii) medullary adenocarcinoma without age limitation, 
iii) breast adenocarcinoma and ovarian cancer. Male breast cancer was also considered for 
genetic testing. Family history was defined as either i) 3 breast cancer cases in first- or 
second-degree relatives in the same lineage, ii) 2 breast cancer cases in first- or second-degree 
relatives (with a transmitting male), with one cancer before the age of 40 or one cancer before 
50 and the other before 70 iii) 1 breast cancer case and one first- or second-degree relative 
(with a transmitting male) with ovarian cancer. During the course of this study, and in line 
with French recommendations, inclusion criteria were recently extended to women with 
isolated ovarian adenocarcinoma before the age of 70 (http://www.e-cancer.fr/les-
soins/oncogenetique). A consecutive series of 1,525 ascertain d cases, mostly of Caucasian 
descent, were studied. All patients attended a visit with a geneticist and a genetic counselor in 
a family cancer clinic, mostly at the Institut Curie, Paris, France. Patients gave their informed 
consent for BRCA1/2 gene analyses. . 
 
 
Nucleic acid extraction 
For mutation scanning purposes, DNA was extracted from 2 ml whole blood samples 
collected on EDTA using a modified perchlorate/chloroform procedure (first 465 samples), as 
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previously described(Johns and Paulus-Thomas, 1989), or the NucleoSpin blood L kit from 
Macherey Nagel (following 849 samples) or the Quickgene 610-L automated system from 
FujiFilm (last 211 samples) according to the manufacturer’s instructions. Three different 
extraction procedures were used during this study in the context of a constant effort to reduce 
the time and labor involved, finally leading to the semi-automated solution from FujiFilm. 
DNAs were calibrated to 50 ng/µl by UV spectrophotometric assay (Nanodrop). Absorbance 
ratios (260/280) and (260/230) had to be in the 1.8-2.0 and 2.0-2.2 ranges, respectively. 
 
 
Enhanced Mismatch Mutation Analysis (EMMA) 
 
 Primer design. Primers were purchased from Fluigent, Paris, France. BRCA1 and 
BRCA2 coding sequences were divided into 81 amplicons analyzed in 24 multiplex PCRs 
including one internal control for large-scale rearrangement analysis (Primer sequences are 
available from Fluigent). Primers were designed to include flanking intronic sequences 
containing recognized splice sites and avoiding known polymorphism to prevent mispriming. 
Due to the well-known limitations of capillary electrophoresis (Rozycka, et al., 2000) and 
topological effects (Weber, et al., 2004), false-negatives can occur in the 70bp from both 
extremities of the amplicon. As a result, larger and overlapping amplicons were designed so 
that the sequence of interest always fell outside these 70bp in at least one amplicon (Weber, et 
al., 2006). One primer of each pair was labeled with 6-carboxyfluorescein (6-FAM). 
 
Amplicon synthesis. Primer mixes were prepared according to the manufacturer’s 
instructions (Fluigent) and all multiplex PCRs were performed using a single condition with 
the Qiagen Multiplex PCR kit (Qiagen, Courtaboeuf, France). Briefly, samples were 
generated in a 10-µl reaction volume containing 100 ng of genomic DNA, 1µl i.e. 0.3 µM of 
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primer mix (Fluigent), 2µl of water and 5µl i.e. 1X Qiagen Multiplex PCR Master mix 
supplied by the manufacturer (Qiagen). The PCR programs were run in a GeneAmp 9700 
thermocycler (Applied Biosystems, Courtaboeuf, France) and consisted of a first denaturation 
step at 95°C for 15 min, followed by 23 cycles of denaturation at 94°C for 30 s, annealing at 
58°C for 90 s and extension at 72°C for 90 s, followed by a final extension at 72°C for 10 
min. PCR products were denatured for 5 min at 96°C then gradually reannealed at -1°C/min 
to reach 25°C. On completion of PCR, PCR products were stored at -20°C until migration. 
  
 Analysis. PCR tube volume was completed with pure water up to 20µL. Wells in 
columns A and H were filled with 1 µL EMMA buffer 10x  to compensate for the higher 
intensity of the capillaries at the extremities of the area. PCRs were electrophoresed with a 
single analytical condition (15kV at 30°C and a fifty cm length-to-detector array) on an 
ABI3100 (Applied Biosystems) using EMMA polymer and according to the manufacturer’s 
instructions (Fluigent, Paris, France). Data were analyzed using dedicated software 
(Emmalys, Fluigent). Electrophoregrams were examined and scored by two operators.  
 
Point mutations. PCR products showing abnormal EMMA profiles (e.g. multiple peaks, 
shouldering or peak widening) were re-amplified, purified and sequenced in both directions 
using the BigDye Terminator Cycle Sequencing V1.1 Ready Reaction kit (Applied 
Biosystems) with incorporation of the PCR oligonucleotides as extension primers, followed 
by electrophoresis in an ABI PRISM 3130XL Genetic Analyzer with analysis using the 
Collection and Sequence Analysis software package (Applied Biosystems). Nucleotide 
position was numbered on the basis of the coding sequence NM_007294.2 and NM_000059.3 
for BRCA1 and BRCA2, respectively. Nucleotide numbering reflects cDNA numbering with 
+1 corresponding to the A of the ATG translation initiation codon in the reference sequence  
according to recommended guidelines (available at http://www.emqn.org/emqn.php and 
Page 7 of 47
John Wiley & Sons, Inc.
Human Mutation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 8 
www.hgvs.org/mutnomen). The initiation codon is codon 1. Electrophoregrams were 
examined and scored by two operators. All mutations were confirmed on a second blood or 
buccal swab sample. 
 
 Large rearrangements. EMMA and quantitative multiplex PCR of short fluorescent 
fragments (QMPSF) were both used to screen for BRCA1 and BRCA2 rearrangements because   
automated profile analysis was easier with QMPSF (see below). QMPSF was used as 
previously described (Casilli, et al., 2006)   . All rearrangements were confirmed on a second 
blood sample and using another technique e.g. long range PCR, transcript analysis or a 
dedicated array-CGH (Rouleau, et al., 2007) . Spurious single-exon deletions due to 
mispriming were therefore unambiguously excluded. 
 
Unknown Variants (UVs) interpretation 
 In silico analysis. Unfortunately, one half of the variations observed in the BRCA1/2 
genes are UVs (Hofstra, et al., 2008), making biological and clinical interpretation a 
challenging task and consequently leading to clinically difficult situations. To facilitate 
subsequent genetic counseling, all identified UVs were submitted to in silico analysis using 
Alamut (Interactive Biosoftware), a decision-support system for mutation interpretation that 
integrates a splice prediction module. Apart from the impact on splicing, unknown variants 
were also analyzed for their putative “protein-based” impact by cross-species and Grantham 
score (Grantham, 1974) comparisons, and were then scored using an in-house model (Supp. 
Figure S1) validated on a series of 378 hereditary breast/ovarian cancer patients and previous 
literature [unpublished data, available on request]. Variants were classified as neutral or of 
little clinical significance below 6 and worthy of complementary investigations (e.g. 
cosegregation analyses or functional studies) above 12. In such cases, the clinical context was 
also thoroughly discussed with the clinical geneticist. 
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Transcript analysis. Patients harboring unknown variants putatively leading to splice 
defects following Alamut in silico analyses were further investigated at the cDNA level. 
Based on previous knowledge (Houdayer, et al., 2008), defects were defined as a minimum 
10% decrease of the wild-type score. Emergence of a cryptic splice site was considered 
significant and worthy of RNA study when it scored at least 50% of the corresponding wild-
type score. ESEs were not considered for routine purposes. 
RNA was extracted from lymphoblastoid cell lines with and without puromycin treatment. 
RNA was reverse-transcribed (Houdayer, et al., 2004) and the BRCA1/2 coding sequence 
surrounding the region of interest was amplified (primer sequences available on request). 
Amplicons were purified and sequenced in both directions using the BigDye Terminator 
Cycle Sequencing V1.1 Ready Reaction kit (Applied Biosystems) with incorporation of the 
PCR oligonucleotides as extension primers, followed by electrophoresis in an ABI PRISM 
3130XL Genetic Analyzer with analysis using the Collection and Sequence Analysis software 
package (Applied Biosystems). Normal controls were always included in these experiments.  
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RESULTS 
 
An EMMA-based strategy was designed for fast screening of BRCA1 and BRCA2 
point mutations and large rearrangements in 1,525 unrelated hereditary breast and/or ovarian 
cancer (HBOC) patients: 1,153 patients were screened in a routine setting following a 
validation step enrolling 372 patients. 
 
Validation step 
 
Point mutations. Before implementing EMMA as a routine diagnostic technique, a 
panel of known BRCA mutations was tested (Weber, et al., 2004; Weber, et al., 2006) [and 
author’s unpublished data]. A series of blind studies were then performed using DHPLC and 
QMPSF as reference techniques for point mutation and large rearrangement screening, 
respectively. DHPLC was chosen as a reference because it is considered to be the gold 
standard for mutation prescreening with more than 1,000 PubMed references 
[http://www.ncbi.nlm.nih.gov/sites/entrez]. Moreov r, our laboratory has an extensive 
experience with this technique, with more than 4,000 patients screened for BRCA1/2 and RB1 
point mutations (Houdayer, et al., 2004; Wagner, et al., 1999) and, more recently, large-scale 
rearrangements using the DHPLC-derived technique called MP/LC (Dehainault, et al., 2004). 
The blind studies involved a total of 372 patients. Two hundred and seventy nine cases were 
first screened on BRCA1 by Fluigent in their mutation detection facility, and 93 cases were 
then screened on both BRCA1 and BRCA2 in our laboratory. PCR conditions and analyses 
were as described above. An equivalent sensitivity was demonstrated, as 127 variations 
(excluding polymorphisms) were found with both techniques. Actually, one variation was 
missed by EMMA (BRCA2, c.9364G>A/p.Ala3122Thr), but another variation missed by 
DHPLC was detected by EMMA (BRCA1, c.2311T>C/p.Leu771Leu).  
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Large rearrangements. The principle of the method consists of quantitative evaluation 
of the relative proportion of a given fragment in the unknown sample with respect to a normal 
control. In order to compare two fragments amplified in two different tubes, peak intensities 
and areas are normalized to a non-mutated DNA fragment used as an internal control. 
Fluorescence intensities were then normalized by adjusting the peaks and areas obtained for 
the control amplicons to the same level and the yield of each amplicon in the various samples 
was evaluated. As some profiles exhibit variations due to polymorphisms, rare variants and 
mutations, Emmalys analyzes variant and non-variant profiles separately and deletions are 
detected by a 50% decrease in peak intensity and area, while duplications are detected by a 
1.5-increase in profile area. Firstly, a 30-sample dedicated large rearrangement panel was 
blindly tested using this procedure. This panel included 20 BRCA1 large rearrangements 
(deletions and duplications) and 10 normal controls. All samples were correctly scored. The 
second step of the validation consisted of identification of 3 large rearrangements present in 
the 372 patients. Two deletions encompassing exons 15 and 16 and 13 to 15, respectively, 
were correctly detected. The third deletion, a deletion of BRCA1 promoter, was not detected 
because the current EMMA primer panel does not explore this part of the gene (which is 
covered by our QMPSF assay).  
Interpretation of polymorphisms according to their profiles.  
One of the main challenges with prescreening methods is the correct identification of 
polymorphisms. This does not constitute an issue for genes with a very low polymorphic 
content such as RB1 but is a major hurdle for BRCA genes, which exhibit a large number of 
polymorphisms throughout their sequence. In this case, the advantages of prescreening 
methods are lost if each variant peak has to be sequenced (Mattocks, et al. 2010). The 
situation becomes much simpler if the method allows correct recognition of polymorphisms 
according to their profile. This requires a high profile specificity and reproducibility. Profiles 
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of distinct mutations from the same fragment must therefore be distinguished, and for the 
same variant, the same profile should be observed in independent experiments. 
Reproducibility was evaluated within series and between series, by superimposition of 
profiles from the same variant. Profiles matched very accurately (Figures 1A, B). A high 
profile specificity was also observed, as illustrated e.g. Figure 2 illustrating  2 polymorphic 
profiles and the co-occurrence of these two polymorphisms in the same patient. 
Polymorphisms were consequently expected to be identified from their variant profile. To 
validate this hypothesis, all variant profiles interpreted as polymorphisms in this series of 93 
patients were sequenced (for a total of 1,200 sequences), and sequencing results were 
compared to EMMA interpretation. In every case, the expected polymorphism was found and 
no extra polymorphism was found in the remaining variant profiles, corresponding to  a 
sensitivity and specificity of 100% in this series. To ensure correct interpretation, 
polymorphisms should be interpreted together and compared between each other instead of 
being compared to a normal control. 
 
Mutations Identified in Routine Screening 
 
DNAs from 1,153 hereditary breast/ovarian cancer patients were subjected to routine 
EMMA screening followed by sequencing of variant fragments. An average of 10 to 15% of 
PCRs had to be re-amplified due to low signal-to-noise ratio (see discussion section) and 3% 
of variant amplicons were sequenced. The 137 mutations found are reported in Supp. Tables 
S1A-B. The overall mutational detection rate according to our inclusion criteria was 11.9% 
i.e. 6% and 5.9% on BRCA1 and BRCA2, respectively. The unknown variant detection rate 
(Supp. Table S2) was 33.5% i.e. higher than previously reported because of the length of the 
intronic sequences analyzed that includes a 70bp “safe zone” (see “primer design”). This 
increased number of intronic UVs may represent a drawback of the design which is why 
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subsequent in silico splice analysis is recommended to confidently predict their putative 
impact on splicing. UV detection rate was approximately twofold higher in BRCA2 (23.8%) 
than in BRCA1 (9.7%). This figure is explained by the respective length of their coding 
sequences, which in turn means that fewer mutations are found in BRCA2 as compared to 
BRCA1.Mutations were similar in type and relative proportion in BRCA1 and BRCA2 (Table 
1). They mainly resulted in  truncated proteins or RNA decay. BRCA2 yielded a slightly 
higher rate of frameshift mutations, due to a greater number of frameshift deletions (51.5% vs. 
33.3% of the mutational spectrum for BRCA2 and BRCA1, respectively). Frameshift 
mutations are by far the largest class of mutations, followed by nonsense and splice mutations 
(average 20% and 9% for both genes). Other mutations comprised rare mutations, i.e. 
missense, in-frame and large rearrangements. Four large rearrangements were found on 
BRCA1 and 2 on BRCA2. In other words, point mutations and large rearrangements accounted 
for 94.2% and 5.8% of the mutational spectrum of BRCA1, respectively. For BRCA2, point 
mutations accounted for 97.1% of the mutational spectrum whereas large rearrangements 
represented 2.9% of the mutational spectrum  
The most frequent mutations found were c.5266dupC on BRCA1 and c.2808_2811del on 
BRCA2 (each found 6 times) followed by BRCA2 c.5946delT (4 times). Four other mutations 
were each found 3 times, i.e. c.1A>G, c.68_69del and c.4986+6T>C on BRCA1 and 
c.1773_1776del on BRCA2. This lack of frequent mutations probably reflects the mixed 
ethnic origin of the study population derived from Paris and suburbs. 
According to our criteria, 18 UVs putatively leaded to a splice anomaly. Lymphoblastoid cell 
lines were available in 10 cases and another blood sample has yet to be obtained from the 
remaining 8 cases. Two UVs on both BRCA1 and BRCA2 actually lead to a splice defect. The 
c.547+3A>T / IVS08+3A>T and c.4484G>T / p.Arg1495Met on BRCA1 showed decrease of 
the donor site with subsequent exon 8 and exon 14 skipping, respectively. The c.316+5G>C / 
Page 13 of 47
John Wiley & Sons, Inc.
Human Mutation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 14 
IVS03+5G>C and the c.7975A>G / p.Arg2659Gly on BRCA2 also showed decrease of the 
donor site with subsequent exon 3 and exon 17 skipping. 
Apart from splicing, 3 other UVs were prominent protein-damaging candidates with scores 
greater than 16 i.e. c.92T>A/p.Ile31Asn and c.122C>T/p.Pro41Leu, c.280C>T/p.Pro94Ser on 
BRCA1 and BRCA2, respectively. They are included in class 4 of the recently proposed 
classification system (Plon, et al., 2008). 
 
Throughput 
Patients were initially analyzed by series of 96, according to the same organization as 
previously used with DHPLC. Following a learning curve period, series of 30 patients were 
subsequently analyzed. It now takes seven working days for complete BRCA1/2 screening in 
30 patients by one technician (excluding DNA extraction and sequencing).
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DISCUSSION 
 
One thousand five hundred and twenty five unrelated breast and/or ovarian cancer 
patients were studied, as part of the routine clinical management provided by the Institut 
Curie, Paris, France. To our knowledge, this is the largest complete mutational screening of 
BRCA1/2 genes reported to date in Europe. 
 
EMMA  
 
This is the first report of a large-scale study using EMMA, some aspects of this 
methodology therefore need to be discussed. Capillary electrophoresis was developed as an 
attractive strategy for mutation detection in the early 1990’s (Khrapko, et al., 1994). However, 
its broad diffusion was hampered by design constraints and lack of sensitivity (Rozycka, et 
al., 2000). The recently described Heteroduplex Analysis by Capillary Array Electrophoresis 
(Perez-Cabornero, et al., 2009), also called Conformation-Sensitive Capillary Electrophoresis 
(CSCE)(Mattocks, et al. 2010) represents a real improvement, but it also presents certain 
disadvantages. It uses a home-made polymer recipe that does not allow batch-to-batch 
reproducibility. Consequently, all fragments with altered peak patterns need to be sequenced, 
dramatically increasing the amount of sequencing needed for genes such as BRCA1/2, which 
involve frequent polymorphisms; large rearrangements cannot be detected and mutational 
screening must be completed by another method.. EMMA retains the simplicity and 
throughput of CSCE, but as a result of a series of additional developmentscomprising 
industrialized ready-to-use separation matrix and specific software, it overcomes the above 
limitations. It allows easy and reliable recognition of polymorphisms according to their 
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profile, and it is the first technique able to detect large rearrangements and point mutations in 
a single run (Weber, et al., 2007).  
 . Some technical remarks and guidelines for implementation and use, based on our 
experience, are listed below. Regarding DNA extraction, 3 different procedures were used 
during the course of the study (see Materials and Methods” section) without any incidence on 
data quality. Due to its high sensitivity, in order to take full advantage of the potential of the 
technique for direct polymorphism identification, specific PCR amplifications must be used 
since nonspecific products could generate shouldering for a wild-type sample, making the 
profile difficult to interpret. Nonspecific products may also be generated by primer 
degradation with time, but this is easily detected because profiles lose their reproducibility.  
Capillary electrophoresis always involves slight run-to-run and capillary-to-capillary mobility 
shifts, so it is therefore important to compare peaks after correct peak alignment, which can be 
tricky with conventional software in the case of complex profiles. The Emmalys software 
appeared to effectively deal with this difficulty, as suggested by the robustness of 
polymorphism analysis.  
Strikingly, heteroduplexes could be either slower or faster than homoduplexes and no rule 
was found that could link one type of nucleotide substitution to one type of mobility 
difference or profile shape. Electrophoretic mobility does not only depend on the mismatch 
bases, but also on the local sequence environment of this mismatch, since distortions of the 
DNA helix at one base pair are propagated to the neighboring bases(Weber, et al., 2004). As a 
consequence of the above, a heteroduplex can exceptionally comigrate with the peak 
corresponding to the following/preceding peak in the multiplex electrophoregram. Therefore, 
if an amplicon from a patient shows an abnormal profile, but does not show any variation on 
sequencing, it could indicate that the altered amplicon is actually a neighboring amplicon. 
This can be easily confirmed by observing the result of large rearrangement analysis, which 
should in turn mimic a deletion on the neighboring peak. Similarly, the quantitative analysis 
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used to detect large rearrangements can also be helpful to detect allele drop-out due to 
mispriming. This information is important in order to detect situations in which one allele 
would not be amplified and therefore not analyzed. Moreover, the nucleotide variation 
inducing the mispriming can also be deleterious. Obviously, in such a case another primer 
pair must be used to distinguish this allelic drop-out from a bona fide deletion.  
Finally, to ensure reliable and easy interpretation of polymorphisms, it is recommended to 
work on series of 30 samples or more. Below this range, it may prove difficult to correctly 
interpret polymorphism profiles because of an insufficient number of reference profiles.  
Distinct injection protocols are available to ensure optimum results (EMMA high-low). In a 
first, “low” injection mode, samples are injected for 10s - 20s at 1kV – 4kV then 
electrophoresed at 15kV for 45 min. This injection mode has a sufficiently low consumption 
to allow  a second run to be performed from the same sample using a “higher injection” 
protocol, in the event of occasional unexpected problems (missed injection, capillary failure, 
microbubble, etc). All of these “tricks”, recommendations and checkpoints are summarized in 
the Analysis Pipeline, Figure 3.  
The viscosity of EMMA separation medium is high r than that of other solutions 
conventionally used in ABI instruments. This requires certain modifications of the capillary 
filling and apparatus operation sequences (provided by Fluigent), compared to standard 
procedures. For instance, this involves longer array filling time, capillary rinsing with buffer 
every 100 runs, and capillary array exchange every 400 runs. Replacing EMMA buffer 1x 
daily is also recommended to avoid loss of resolution. System performance and integrity 
should be checked once a week using a control sample (a 4-plex PCR with variant profiles for 
each peak, available from Fluigent). As for any heteroduplex analysis, homozygous mutations 
cannot be detected by EMMA on the direct sample, but this can be circumvented by adding a 
wild-type DNA in the sample to force heteroduplex formation, as previously demonstrated 
with DHPLC (Ferec, et al., 2004). 
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In addition to the above precautions and issues, which require the level of care typically 
required by molecular diagnosis, EMMA uses standard and well-known sequencers and a set 
of ready-to-use reagents, thereby facilitating upgrading to this new technology.  
The cost of consumable items used to screen BRCA1 and BRCA2 by EMMA is estimated to 
be less than 100 euros per patient (based on price list). This estimation excluded the costs of 
DNA extraction and sequencing, purchase of the sequencer, instrument depreciation and 
labor. The markedly reduced need for downstream sequencing (typically 3%), as a result of 
polymorphism identification, is also a factor for cost reduction (Sevilla, et al., 2002).  
This technology allows a high throughput and our laboratory now generates close to 9000 
amplicons per month for diagnostic purposes; it should be stressed that the management of 
such a large volume of data requires a robust data management system. We have therefore 
constructed a FileMakerPro® database which integrates information from sampling to the 
final report, but which also interacts with the Institute’s databases. This allows careful follow-
up of the entire analysis [Laugé A et al., poster 664 Assises de Génétique 2010]. 
The advantages of EMMA  compared to our previous DHPLC-based strategy are 
obvious: they comprise a single  condition for amplification and run, a higher throughput and 
lower costs (lab technician time decreased to one quarter and overall cost decreased to one 
third, compared to DHPLC in our hands). The simultaneous detection of point mutations and 
large rearrangements is another advantage. However promoter regions are not covered and 
this must be taken into account, since deletions of the promoter regions are a probably rare but 
significant cause of HBOC (Brown, et al., 2002; Caux-Moncoutier, et al., 2009). Although 
technical performance was acceptable, the complexity of the currently available Emmalys 
interface prevents routine use of large rearrangement detection. On the other hand, Emmalys 
was found to be robust and user-friendly for point mutation detection. 
 
Page 18 of 47
John Wiley & Sons, Inc.
Human Mutation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 19 
More generally, we believe EMMA should be considered as an alternative to the High 
Resolution Melting curve analysis (HRM) technique. HRM is a very fast and elegant tube-
method also allowing simultaneous detection of point mutations and large rearrangements in 
one experiment (Coulet, et al., 2010 ; Rouleau, et al., 2009). Its main advantage over EMMA 
is the absence of post-PCR manipulation. However, based on the recent literature, HRM 
appears to have a number of drawbacks (which are overcome by EMMA), notably:  
i) its sensitivity depends on the nucleotide composition of the amplicon (melting domains). 
HRM diagnostic guidelines for BRCA1 screening recommend extreme caution when 
analyzing high-GC, low-GC contents and fragments containing many different variants (van 
der Stoep, et al., 2009; Wittwer, 2009)  
ii) interpretation of polymorphisms according to their profile would need probes or sequence 
analysis to exclude the presence of a mutation with an identical melt profile(Nguyen-Dumont, 
et al., 2009).  
 
Spectrum of Mutations 
 
The mutation detection rate in BRCA genes largely depends on the patient inclusion 
criteria and selecting high-risk patients from breast and ovarian families would provide the 
geneticist with a higher mutation detection rate than including patients based exclusively on 
their personal history. That being said, the sensitivity of EMMA was 11.9% in our series of 
1,153 patients, which is in line with expectations with regards to patient inclusions and 
compared to previous results using DHPLC as well as data from French laboratories 
(http://www.e-cancer.fr). 
Considering the mutational spectrum, the recurrent so-called Ashkenazim mutations (BRCA1 
68_69del, 5266dupC and BRCA2 5946delT) represented 9.5% of our identified mutations, 
which is why prescreening for these 3 mutations is proposed during genetic counseling to 
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patients reporting an Eastern European origin. Apart from these mutations, we did not observe 
a larger panel of recurrent mutations which would justify a first-line screening procedure, as 
described in other populations (Revillion, et al., 2004). Few deleterious inframe/missenses 
mutations were found but this could actually reflect an interpretation bias in view of the fact 
that 386 unknown variants were detected (detection rate 33.5%). In other words, these 386 
variants no doubt included deleterious neutral/missense/intronic mutations, which is why 
scoring variants to highlight prominent candidates for future collaborative studies is of special 
relevance for optimization of molecular diagnosis. There is considerable debate about the 
usefulness of large rearrangement screening in BRCA genes. The main argument against such 
screening, is that the time and efforts needed for such screening might be used more 
efficiently by screening more patients but for point mutations only. Previous reports (Engert, 
et al., 2008; Mazoyer, 2005)suggested that large rearrangements accounted for an average of 
10% of the BRCA1 mutational spectrum. Although our present results are lower (5.8%), we 
can confidently confirm that it is worth searching for BRCA1 large rearrangements in genetic 
diagnosis, regardless of the patient’s family history. The situation is less clear for BRCA2 
because previous studies, including those from our t am (Casilli, et al., 2006; Tournier, et al., 
2004),  were based on smaller series and selected high-risk families (Agata, et al., 2005; 
Engert, et al., 2008; Woodward, et al., 2005). These studies led to the overall conclusion that 
BRCA2 genomic rearrangements are worth investigating in high-risk families. This does not 
mean that these mutations are associated with a higher risk, but that due to the very low 
contribution of large rearrangements in the BRCA2 mutational spectrum, the search for these 
mutations should be limited to patients with a severe family history associated with a high 
BRCA2 mutation detection rate. Two BRCA2 large rearrangements, one complete deletion and 
one duplication of exons 19, 20 (Figure 4) were found in the present series of 1,153 
consecutive patients. The deletion was found in a young breast cancer patient with no family 
history i.e. a low-risk case. Conversely, the duplication was found in a high-risk family: the 
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index case and her older sister developed bilateral breast carcinoma at 48, 64 and 57, 63 years 
of age, respectively. Their paternal aunt and grandmother also developed breast cancer at 45 
and 61 years of age, respectively. The overall probability of identifying a BRCA mutation in 
our index case was 59.4% (24.6% for BRCA1 and 34.9% for BRCA2) according to the 
BRCAPRO model (Parmigiani, et al., 1998) and 57.9%(12.1% for BRCA1 and 45.8% for 
BRCA2)  according to the BOADICEA model (Antoniou, et al., 2008). Interestingly, her older 
affected sister was found to be negative  using a combination of direct sequencing for 
BRCA1/2 and a limited 5-site rearrangement panel for BRCA1(Comprehensive 
BRACAnalysis®, Myriad® Genetics laboratories Inc. Salt Lake City, USA). Following 
identification of the BRCA2 duplication in our index case, genetic testing and appropriate 
genetic counseling were made available to the relatives e.g. 6 unaffected females (at least) and 
the affected sister. As expected, the affected sister carried the BRCA2 duplication. More 
generally, and as this kind of mutation might also be found in low-risk situations, this study 
argues in favor of methods allowing simultaneous and convenient detection of point 
mutations and large rearrangements to enable clinical geneticists to meet the constraints of 
routine genetic testing.  
 
General conclusions and perspectives 
 
The main advantages of EMMA are that it provides a marked increase of throughput 
(or cost reduction at a given throughput) compared to DHPLC and is based on standard 
sequencers routinely used in laboratories. It can therefore be easily implemented in 
laboratories familiar with capillary electrophoresis, and allows screening and sequencing on 
the same platform. Due to its flexibility, EMMA could also be used for rapid BRCA screening 
of a subset of patients e.g. before poly(ADP-ribose) polymerase inhibitor treatment (Audeh, et 
al., 2010 ; Tutt, et al. 2010). 
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Finally, the future of EMMA should be considered in the context of growing 
sequencing capacities provided by the next-generation-sequencing (NGS) platforms. Since 2 
SOLiD NGS platforms (ABI-Life technologies) are available in our Institute, we tested this 
technology for BRCA diagnostic applications [Houdayer C et al., European Society of Human 
Genetics meeting 2010, P11.089]. The SOLiD chemistry appears to be reliable for diagnostic 
purposes, but implementation of a SOLiD diagnostic pipeline remains complex at the present 
time for reasons of sample preparation, bioinformatics, fast-evolving protocols and costs. 
EMMA obviously cannot compete with SOLiD in terms of throughput, but indeed only a 
small number of diagnostic laboratories actually need such amazing sequencing capacities. 
The throughput and therefore data handling constraints of the 454 NGS machine (Roche) are 
still enormous, although lower than those of SOLiD, but well known sensitivity/specificity 
problems in homopolymer runs have to be taken into account (Emrich, et al., 2007; Wicker, et 
al., 2006). The present study therefore suggests that EMMA represents a valuable short-term 
and medium-term option for many diagnostic laboratories looking for an easy, reliable and 
affordable strategy, enabling fast and sensitive analysis for a large number of genes. 
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FIGURE LEGENDS 
 
 
Figure 1A. Reproducibility between series. 
Screenshot from Emmalys showing superimposition of 5 different samples harboring the 
same polymorphism (BRCA2 exon 2), from 5 different series of 93 patients. 
 
Figure 1B. Reproducibility within series. 
Screenshot from Emmalys showing superimposition of 33 different samples harboring the 
same polymorphism (BRCA1 exon 13), from a series of 93 patients. 
 
Figure 2. Profile specificity  
Screenshots from Emmalys with 3 polymorphic profiles from 2 adjacent codons (BRCA1 
exon 11). In grey: normal monomorphic profile, in black: polymorphic profiles. From left to 
right: c.2077G>A/p.Asp693Asn, c.2082C>T/p.Ser694Ser and the combination of both 
(c.2077G>A/p.Asp693Asn plus c.2082C>T/p.Ser694Ser). All polymorphic profiles are 
clearly distinct. 
 
Figure 3. EMMA : analysis pipeline 
Schematic representation of a routine EMMA analysis. 
 
 
Figure 4. Duplication of BRCA2 exons 19 and 20. 
Three screenshots from Emmalys showing the 3 multiplex PCRs incorporating BRCA2 exons 
19 and 20 (panels A, B and C). Exons under study and the amplicon number (when the exon 
is investigated in overlapping amplicons) are indicated at the top of the corresponding peaks. 
The electrophoregrams in grey and black represent a normal control and the duplicated 
patient, respectively. Profiles are superimposed then normalized using the internal 
control.Two ratios are used to determine the presence or absence of a large-scale 
rearrangement: R1 is the ratio between peak intensity of the fragment of interest over peak 
intensity of the internal control. R2 (indicated for each peak) is the ratio of R1 of the sample 
of interest over control R1 defined as a mean R1 value based on several control samples. 
Duplicated exons are indicated by an arrow. Exon 19 is investigated in 2 overlapping 
amplicons (upper panels A, B), while exon 20 is investigated with a single amplicon (bottom 
panel C). 
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Tables 
 
Table 1. Deleterious mutations found according to their type. 
 
 
 BRCA1 (number and %) 
 
BRCA2 (number and %) 
 
Frameshift 
 
 
37 (53.6%) 
 
47 (69.1%) 
 
Nonsense 
 
 
16 (23.2%) 
 
 
13 (19.1%) 
 
Splice 
 
 
8 (11.6%) 
 
 
4 (5.9%) 
 
Large rearrangements 
 
 
4 (5.8%) 
 
 
2 (2.9%) 
 
Missense 
 
 
4 (5.8%) 
 
 
1 (1.5%) 
 
In frame 
 
 
0 (0%) 
 
 
1 (1.5%) 
 
Total 
 
 
69 (100%) 
 
 
68 (100%) 
 
Mutation detection rate 
(1153 patients) 
 
 
6% 
 
5.9% 
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Supplementary Figure S1. In-house algorithm for UV scoring 
A restrictive definition of functional domains was used to avoid redundancy between 
“conservation across species” and “known functional domain” items. The amino-acid 
positions 24-64 (RING finger), 503-508 (SLN1), 607-615 (SLN2), 1189, 1457, 1524, 1542 
(serine phosphorylation sites), 1649-1736 (BRCT1) and 1756-1855 (BRCT2) were therefore 
considered as functional domains for BRCA1. Functional domains for BRCA2  were as 
follows: amino-acid positions 18-105 (transactivation), 987-1069, 1198-1293; 1407-1498 ; 
1501-1589; 1649-1735; 1822-1914; 1955-2035; 2036-2112 (BRC repeats), 3263-3269 
(SLN1) and 3381-3385 (SLN2). Scores from 12 and above are considered “likely 
deleterious”. 
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Supplementary Table S1A. Deleterious mutations found on BRCA1  
Recurrence numbers are in brackets. Nucleotide position was numbered on the basis of the 
coding sequence NM_007294.2. Nucleotide numbering reflects cDNA numbering with +1 
corresponding to the A of the ATG translation initiation codon in the reference sequence. The 
initiation codon is codon 1. 
 
Site Description Expected Consequence 
Exons 1-2 c.-200-?_80+?del 
(deletion of exons 1 and 2) 
  
c.1A>G (3) p.Met1? 
c.19_47del29 p.Arg7_Asn16>CysfsX24 
Exon 2 
c.68_69delAG (3) p.Glu23ValfsX17 
Intron 2 c.81-2A>G   
Exon 5 c.140G>A p.Cys47Tyr 
c.212+3A>G   Intron 5 
c.213-02A>C   
Exon 7 c.342_343delTC p.Pro115X 
Exons 8 to 13 c.442-?_4357+?del 
(deletion of exons 8 to 13) 
  
Exon 9 c.569_570insAACG p.Val191ThrfsX3 
c.800C>G p.Ser267X 
c.815_824dup10 p.Thr276AlafsX14 
c.843_846del4 p.Ser282TyrfsX15 
c.928C>T p.Gln310X 
c.1016dupA p.Val340GlyfsX6 
c.1121delC p.Thr374AsnfsX2 
c.1953_1956del4 p.Lys653SerfsX47 
c.2197_2201del5 p.Glu733ThrfsX5 
c.2269delG p.Val757PhefsX8 
c.2308delT p.Ser770HisfsX22 
c.2561_2565del5 p.Ala854ValfsX47 
c.2952delT p.Ile986SerfsX14 
c.3285delA p.Lys1095AsnfsX14 
c.3377delC p.Pro1126HisfsX3 
c.3403C>T p.Gln1135X 
c.3417delT p.Ser1139ArgfsX16 
c.3428delCinsTA p.Ser1143LeufsX6 
c.3481_3491del11 p.Glu1161PhefsX3 
c.3593T>A p.Leu1198X 
c.3648dupA p.Ser1217IlefsX2 
c.3700_3704del5 p.Val1234GlnfsX8 
c.3748G>T p.Glu1250X 
c.3753T>A p.Cys1251X 
c.3756_3759del4 p.Ser1253ArgfsX10 
c.3771_3778del8 p.Glu1257AspfsX7 
c.3839_3843del5ins4 p.Ser1280X 
c.3841C>T p.Gln1281X 
c.3937C>T p.Gln1313X 
c.4065_4068del4 p.Asn1355_Gln1356>LysfsX10 
Exon 11 
c.671-?_4185+?del 
(deletion of exons 11 and 12) 
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Site Description Expected Consequence 
Exon 12 c.4165_4166delAG p.Ser1389X 
c.4201C>T p.Gln1401X 
c.4258C>T p.Gln1420X 
Exon 13 
c.4327C>T p.Arg1443X 
c.4372C>T p.Gln1458X Exon 14 
c.4484G>T (2) p.Arg1495Met 
c.4810C>T p.Gln1604X Exon 16 
c.4945_4947delAGAinsTTTT (2) p.Arg1649PhefsX30 
Intron 16 c.4986+6T>C (3)   
Exon 17 c.5071dupA p.Thr1691AsnfsX4 
Exon 20 c.5266dupC (6) p.Gln1756ProfsX74 
Exons 21 to 24 c.5278-?_*1381+?del 
(deletion of exons  21 to 24) 
  
Exon 21 c.5307T>A p.Tyr1769X 
c.5503C>T p.Arg1835X Exon 24 
c.5541C>A p.Cys1847X 
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Supplementary Table S1B. Deleterious mutations found on BRCA2 
Recurrence numbers are in brackets. Nucleotide position was numbered on the basis of the 
coding sequence NM_000059.3. Nucleotide numbering reflects cDNA numbering with +1 
corresponding to the A of the ATG translation initiation codon in the reference sequence. The 
initiation codon is codon 1. 
 
Site Description Expected Consequence 
Exons 1 to 27 c.( ?_-227)_(*902_ ?)del 
(complete deletion) 
  
c.145G>T (2) p.Glu49X Exon 3 
c.289G>T p.Glu97X 
Intron 6 c.516+1G>T   
c.1238delT p.Leu413HisfsX17 
c.1310_1313del4 p.Lys437IlefsX22 
c.1511_1512delCT p.Ser504TyrfsX9 
c.1593dupA p.Glu532ArgfsX3 
c.1773_1776del4 (3) p.Ile591MetfsX22 
Exon 10 
c.1813dupA p.Ile605AsnfsX11 
c.1929delG p.Arg645GlufsX15 
c.2588dupA p.Asn863LysfsX18 
c.2612C>A p.Ser871X 
c.2808_2811del4 (6) p.Ala938ProfsX21 
c.2899_2900delCT p.Leu967ArgfsX14 
c.3195delT p.Asn1066IlefsX11 
c.3645_3646del2ins7 p.Phe1216LysfsX14 
c.3744_3747del4 (2) p.Ser1248ArgfsX10 
c.4136dupA p.Ile1380AspfsX2 
c.4284dupT p.Gln1429SerfsX9 
c.4965C>A p.Tyr1655X 
c.5197dupT p.Ser1733PhefsX10 
c.5576_5579del4 p.Ile1859LysfsX3 
c.5616_5620del5 p.Lys1872AsnfsX2 
c.5645C>A p.Ser1882X 
c.5682C>G p.Tyr1894X 
c.5909C>A (2) p.Ser1970X 
c.5946delT (4) p.Ser1982ArgfsX22 
c.6079dupA p.Arg2027LysfsX22 
c.6082_6086del5 p.Glu2028LysfsX19 
c.6275_6276delTT (2) p.Leu2092ProfsX7 
c.6359C>G p.Ser2120X 
c.6373dupA p.Thr2125AsnfsX4 
c.6405_6409del5 p.Asn2135LysfsX3 
c.6644_6647del4 p.Tyr2215SerfsX13 
Exon 11 
c.6656C>G p.Ser2219X 
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Site Description Expected Consequence 
Exon 14 c.7069_7070delCT p.Leu2357ValfsX2 
Exon 15 c.7480C>T p.Arg2494X 
  c.7612A>T p.Lys2538X 
Intron 15 c.7617+1G>T   
c.7680dupT p.Gln2561SerfsX5 
c.7795_7797delGAA p.Glu2599del 
Exon 16 
c.7805G>C p.Arg2602Thr 
c.8021delA p.Lys2674ArgfsX2 
c.8029_8030delGA p.Glu2677LysfsX3 
c.8032-8033dupAG p.Asp2679GlyfsX16 
Exon 18 
c.8207delT p.Leu2736ProfsX2 
Exons 19 to 20 c.8332-?_8632+?dup 
(duplication of  exons 19 and 20) 
  
Exon 20 c.8548_8551del4 p.Glu2850GlnfsX12 
c.9026_9030del5 p.Tyr3009SerfsX7 Exon 23 
c.9097delA p.Thr3033LeufsX29 
c.9154C>T p.Arg3052Trp Exon 24 
c.9253dupA p.Thr3085AsnfsX26 
Intron 24 c.9257-1G>A   
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Supplementary Table S2A. Unknown variants found on BRCA1 
Recurrence numbers are in brackets. Nucleotide position was numbered on the basis of the 
coding sequence NM_007294.2. Nucleotide numbering reflects cDNA numbering with +1 
corresponding to the A of the ATG translation initiation codon in the reference sequence. The 
initiation codon is codon 1. 
 
Site Description Expected Consequence 
Intron 1 c.-19-24A>G   
c.81-178_167del12 (*)   Intron 2 
c.81-14C>T   
Exon 3 c.92T>A p.Ile31Asn 
c.134+149A>C   Intron 3 
c.135-27T>A   
Exon 5 c.199G>T p.Asp67Tyr 
c.301+55G>A   Intron 6 
c.302-24_22delAAT   
c.314A>G p.Tyr105Cys Exon 7 
c.425C>A p.Pro142His 
Intron 7 c.441+52del12 (2)   
c.448A>G p.Thr150Ala 
c.456C>T (2) p.Leu152Leu 
c.466C>A p.Leu156Ile 
Exon 8 
c.536A>G (2) p.tyr179Cys 
c.547+3A>T (2)   
c.548-34T>C 
  
c.548-58dupT   
Intron 8 
c.548-65A>C   
c.593+76C>G   Intron 9 
c.594-34T>C   
Intron 10 c.670+85T>C (2)   
c.981A>G (4) p.Thr327Thr 
c.1456T>C (2) p.Phe486Leu 
c.1487G>A p.Arg496His 
c.1541C>G p.Pro514Arg 
c.1648A>C (2) p.Asn550His 
c.1866G>A p.Ala622Ala 
c.1940G>A p.Ser647Asn 
c.2352G>A p.Ser784Ser 
c.2458A>G p.Lys820Glu 
c.2477C>A (2) p.Thr826Lys 
c.2518A>T p.Ser840Cys 
c.2733A>G (4) p.Gly911Gly 
c.2942C>T p.Pro981Leu 
c.3296C>T p.Pro1099Leu 
Exon 11 
c.3302G>A p.Ser1101Asn 
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c.3305A>G p.Asn1102Ser 
c.3418A>G (4) p.Ser1140Gly 
c.3600G>T p.Gln1200His 
Site Description Expected Consequence 
c.3608G>A p.Arg1203Gln 
c.3640G>A p.Glu1214Lys 
c.3804T>C p.Asn1268Asn 
Exon 11 
c.3823A>G (4) p.Ile1275Val 
Exon 12 c.4113G>A (2) p.Gly1371Gly 
c.4185+3A>T   
c.4185+21delTG   
Intron 12 
c.4185+21_22dupTG 
  
Exon 13 c.4255G>C p.Glu1419Gln 
Intron 13 c.4358-37G>A 
  
Exon 14 c.4445A>G p.Asp1482Gly 
Exon 15 c.4636G>A p.Asp1546Asn 
c.4485-32C>T 
  
Intron 14 
c.4485-57T>C   
c.4675+31C>T   Intron 15 
c.4675+81T>C   
c.4691T>C p.Leu1564Pro 
c.4812A>G p.Gln1604Gln 
Exon 16 
c.4840C>T p.Pro1614Ser 
Exon 17 c.4993G>C p.Val1665Leu 
c.4987-20A>G   Intron 16 
c.4987-25A>G   
c.5074+107C>T   
c.5074+108G>A (3)   
Intron 17 
c.5075-74C>T   
Exon 19 c.5177G>T p.Arg1726Ile 
c.5193+64T>G   
c.5194-14T>A   
Intron 19 
c.5194-165_162dup   
c.5203G>A p.Glu1735Lys Exon 20 
c.5213G>A p.Gly1738Glu 
Intron 20 c.5277+55A>T   
c.5332+182dupA (*)   
c.5332+78C>T   
c.5333-130T>C (2)   
c.5333-44A>T   
c.5333-61G>C   
Intron 21 
c.5333-134C>A (4)   
Intron 22 c.5406+63G>T   
Exon 23 c.5412C>T (2) p.Val1804Val 
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c.5467+148delT   Intron 23 
c.5468-10C>A (2)   
 
(*) these UVs were detected following allele drop-out (see text)
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Supplementary Table S2B. Unknown variants found on BRCA2 
Recurrence numbers are in brackets. Nucleotide position was numbered on the basis of the 
coding sequence NM_000059.3. Nucleotide numbering reflects cDNA numbering with +1 
corresponding to the A of the ATG translation initiation codon in the reference sequence. The 
initiation codon is codon 1. 
 
Site Description Expected Consequence 
c.-11C>T (5)   
c.-12T>C   
Exon 2 
c.64G>A p.Ala22Thr 
c.67+62T>G (12)   
c.67+82C>G (14)   
Intron 2 
c.68-7T>A (7)   
c.122C>T p.Pro41Leu 
c.198A>G p.Gln66Gln 
c.223G>C (3) p.Ala75Pro 
Exon 3 
c.280C>T p.Pro94Ser 
c.316+5G>C   
c.316+6T>C   
c.316+12A>G   
c.316+13A>G   
c.316+57C>T   
c.317-12G>A   
Intron 3 
c.317-92delA   
c.324T>C p.Asn108Asn Exon 4 
c.400C>A p.Leu134Ile 
Intron 4 c.425+52A>G   
c.475+3A>T   
c.476-5C>T   
Intron 5 
c.476-24A>G   
c.516+21A>T (4)   
c.516+54T>C 
  
c.517-19C>T (4)   
c.517-23_22delTA   
c.517-74G>C   
Intron 6 
c.517-89G>A   
Exon 7 c.532A>C p.Lys178Gln 
c.631+18G>A   
c.631+25C>T   
c.631+66C>T   
c.632-16A>C   
Intron 7 
c.632-75T>C   
c.682-30A>C 
  
Intron 8 
c.682-32A>G 
  
c.943T>A p.Cys315Ser Exon 10 
c.978C>A p.Ser326Arg 
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c.986G>C p.Arg329Thr 
c.1096T>G p.Leu366Val 
c.1181A>C p.Glu394Ala 
c.1216G>A p.Ala406Thr 
c.1219C>G p.Gln407Glu 
c.1272A>G p.Ser424Ser 
c.1275A>G p.Glu425Glu 
c.1281C>A p.Asp427Glu 
c.1395A>C p.Val465Val 
c.1514T>C p.Ile505Thr 
c.1561T>G p.Ser521Ala 
c.1786G>C p.Asp596His 
c.1788T>C (5) p.Asp596Asp 
Exon 10 
c.1792A>G (2) p.Thr598Ala 
Intron 10 c.1910-43T>C   
c.1964C>G p.Pro655Arg 
c.1966A>G p.Thr656Ala 
c.2330A>G p.Asp777Gly 
c.2350A>G p.Met784Val 
c.2477A>G p.Glu826Gly 
c.2538A>C (2) p.Ser846Ser 
c.2550A>G (2) p.Gln850Gln 
c.2635T>A p.Ser879Thr 
c.2803G>A (4) p.Asp935Asn 
c.2803G>C p.Asp935His 
c.2817C>T p.Thr939Thr 
c.3097G>T p.Asp1033Tyr 
c.3152T>C p.Leu1051Ser 
c.3264T>C (2) p.Pro1088Pro 
c.3445A>G p.Met1149Val 
c.3515C>T (2) p.Ser1172Leu 
c.3516G>A (3) p.Ser1172Ser 
c.3723T>G p.Phe1241Leu 
c.3749A>G p.Glu1250Gly 
c.3869G>A p.Cys1290Tyr 
c.3949A>T (2) p.Thr1317Ser 
c.4090A>C (5) p.Ile1364Leu 
c.4164T>C p.Thr1388Thr 
c.4199A>G p.His1400Arg 
c.4241C>T p.Thr1414Met 
c.4242G>A p.Thr1414Thr 
c.4271C>G (2) p.Ser1424Cys 
c.4614T>C (2) p.Ser1538Ser 
c.4677T>C p.Phe1559Phe 
Exon 11 
c.4686A>G p.Gln1562Gln 
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c.4850G>A p.Ser1617Asn 
c.4903T>C p.Leu1635Leu 
c.5070A>C p.Lys1690Asn 
c.5268A>G p.Val1756Val 
c.5312G>A (2) p.Gly1771Asp 
c.5418A>G (2) p.Glu1806Glu 
c.5503A>G p.Asn1835Asp 
c.5634C>T p.Asn1878Asn 
c.5688A>G p.Ala1896Ala 
c.5704G>A (2) p.Asp1902Asn 
c.5741G>C p.Ser1914Thr 
c.5745G>A p.Thr1915Thr 
c.5778T>G p.Ser1926Arg 
c.5785A>G p.Ile1929Val 
c.5852G>A p.Ser1951Asn 
c.5896C>T p.His1966Tyr 
c.5928G>T p.Gly1976Gly 
c.5937C>G p.Ser1979Arg 
c.5985C>T p.Asn1995Asn 
c.6215C>G p.Ser2072Cys 
c.6295A>G p.Arg2099Gly 
c.6323G>A (3) p.Arg2108His 
c.6338A>G (2) p.Asn2113Ser 
c.6347A>G (3) p.His2116Arg 
Exon 11 
c.6553G>T p.Ala2185Ser 
Intron 11 c.6842-20T>A 
  
Exon 12 c.6853A>G (2) p.Ile2285Val 
Intron 12 c.6938-26T>C 
  
Exon 13 c.6972T>C pHis2324His 
c.7007+18T>A   
c.7007+53G>A   
Intron 13 
c.7008-44A>G   
c.7017G>C (2) p.Lys2339Asn 
c.7052C>G p.Ala2351Gly 
c.7082A>G p.His2361Arg 
c.7242A>T p.Ser2414Ser 
Exon 14 
c.7319A>G (3) p.His2440Arg 
c.7469T>C p.Ile2490Thr 
c.7478T>G p.Met2493Arg 
c.7534C>T p.Leu2512Phe 
c.7559G>T p.Arg2520Leu 
Exon 15 
c.7565C>T p.Ser2522Phe 
Intron 15 c.7618-74A>G   
c.7805+46C>T   Intron 16 
c.7805+47A>G   
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c.7806-40A>G   
Exon 17 c.7975A>G p.Arg2659Gly 
Intron 17 c.7976+35C>A (2)   
Intron 17 c.7976+57G>C   
c.7994A>G (2) p.Asp2665Gly 
c.8149G>T (2) p.Ala2717Ser 
Exon 18 
c.8182G>A (2) p.Val2728Ile 
Intron 18 c.8331+109G>A (4)   
Exon 19 c.8460A>C (2) p.Val2820Val 
IVS19+19A>G   
c.8487+47C>T (8)   
c.8487+82G>A (3)   
Intron 19 
c.8488-52A>G   
c.8503T>C p.Ser2835Pro 
c.8567A>C (3) p.Glu2856Ala 
Exon 20 
c.8592C>T p.Ala2864Ala 
Intron 20 c.8633-4T>A   
Intron 21 c.8754+75A>G   
c.8850G>T (2) p.Lys2950Asn Exon 22 
c.8904C>T p.Thr2968Thr 
Exon 23 c.9038C>T p.Thr3013Ile 
Intron 23 c.9117+44G>T 
  
Exon 24 c.9216G>A p.Val3072Val 
c.9275A>G p.Tyr3092Cys 
c.9292T>C p.Tyr3098His 
c.9371A>T p.Asn3124Ile 
Exon 25 
c.9373C>T p.Leu3125Phe 
Intron 25 c.9501+4A>G 
  
c.9586A>G p.Lys3196Glu 
c.9606G>C p.Pro3202Pro 
c.9610A>G p.Thr3204Ala 
c.9613_9614delGCinsCT p.Ala3205Leu 
Exon 26 
c.9613G>A p.Ala3205Thr 
c.9648+106delT (4)   
c.9648+64T>C   
c.9648+84G>A (3)   
c.9649-20C>T (2)   
Intron 26 
c.9649-65_62del4 
  
c.9730G>A (2) p.Val3244Ile 
c.9738C>A p.Ala3246Ala 
c.9972A>G p.Pro3324Pro 
c.10045A>G p.Thr3349Ala 
Exon 27 
c.10078A>G p.Lys3360Glu 
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